(Q39984618)

16 September 2017

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor (English)

1 reference

16 September 2017

0 references

8

Catherine M Bollard

1 reference

16 September 2017

7

Cliona M Rooney

1 reference

16 September 2017

5

Malcolm K Brenner

1 reference

16 September 2017

6

Helen E Heslop

1 reference

16 September 2017

2

Gianpietro Dotti

1 reference

16 September 2017

4

Mariam Khalil

1 reference

16 September 2017

Aaron E Foster

1

1 reference

PMCID

2745436

16 September 2017

An Lu

series ordinal

3

1 reference

PMCID

2745436

16 September 2017

language of work or name

1 reference

1 June 2008

1 reference

16 September 2017

Journal of Immunotherapy

1 reference

16 September 2017

31

1 reference

16 September 2017

5

1 reference

16 September 2017

500-505

1 reference

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

16 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Cancer regression in patients after transfer of genetically engineered lymphocytes

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Adoptive immunotherapy for cancer: building on success

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Immunosuppressive networks in the tumour environment and their therapeutic relevance

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Post-transplant lymphoproliferative disorders

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

TGFbeta signaling in growth control, cancer, and heritable disorders

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

The transforming growth factor-beta family

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

In vitro transformation of human B-cell follicular lymphoma cells by Epstein-Barr virus

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2745436

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18463534

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immune escape mechanisms in Hodgkin's disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18463534

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18463534

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/CJI.0B013E318177092B

1 reference

16 September 2017

1 reference

16 September 2017

1 reference

PMCID

2745436